Comparative Pharmacology
Head-to-head clinical analysis: MIRAPEX ER versus PRAMIPEXOLE DIHYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRAPEX ER versus PRAMIPEXOLE DIHYDROCHLORIDE.
MIRAPEX ER vs PRAMIPEXOLE DIHYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-ergot dopamine agonist with high affinity for D2 and D3 receptor subtypes; stimulates dopamine receptors in the striatum.
Non-ergoline dopamine agonist that selectively binds to D2 and D3 dopamine receptors, particularly D3, in the striatum and substantia nigra, mimicking dopamine's effects to improve motor function in Parkinson's disease.
Oral, start 0.375 mg once daily, titrate weekly by 0.375 mg/dose to 1.5 mg once daily (immediate-release); ER: same total daily dose once daily.
0.125 mg orally three times daily, titrated as tolerated to maximum 4.5 mg/day
None Documented
None Documented
Terminal elimination half-life: 8–12 hours in young healthy adults; prolonged to 16–40 hours in elderly (≥65 years) and up to 30 hours in moderate renal impairment (CrCl 20–50 mL/min).
Terminal half-life: 8–12 hours in young adults; up to 15–18 hours in elderly. Clinical context: Once-daily dosing; steady-state in 2–4 days.
Renal excretion of unchanged drug and metabolites: ~90% in urine (pramipexole: ~70% unchanged; N-desmethyl metabolite: ~20%). Fecal excretion: ~2%. Biliary elimination: minimal.
Renal: ~90% unchanged in urine; biliary/fecal: ~2%.
Category C
Category A/B
Dopamine Agonist
Dopamine Agonist